Savara Q2 Loss Widens to $40.2M as Commercial Prep Costs Surge
SVRA has more than doubled off its 52-week low of $2.43.
Summary
Savara's Q2 net loss widened to $40.2M from $30.4M a year ago, driven by a 78% jump in G&A expenses as the company builds out its commercial team ahead of a potential MOLBREEVI launch. R&D spending rose modestly, but the pre-launch cost ramp added $8.3M in G&A alone. Cash stands at ~$173M against ~$30M in debt, providing runway but highlighting the burn rate acceleration. This follows the CFO's departure in July and an FDA review extension to November 2026 for MOLBREEVI. The financials underscore the high-stakes bet on a U.S. approval that remains uncertain.
At the time of this announcement, SVRA was trading at $5.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.43 to $7.01. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.